These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 24619958)
1. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer. Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958 [TBL] [Abstract][Full Text] [Related]
2. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway. Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403 [TBL] [Abstract][Full Text] [Related]
3. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells. Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770 [TBL] [Abstract][Full Text] [Related]
4. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132 [TBL] [Abstract][Full Text] [Related]
6. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Cho SH; Park YS; Kim HJ; Kim CH; Lim SW; Huh JW; Lee JH; Kim HR Int J Oncol; 2012 Jul; 41(1):211-8. PubMed ID: 22552741 [TBL] [Abstract][Full Text] [Related]
7. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661 [TBL] [Abstract][Full Text] [Related]
8. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928 [TBL] [Abstract][Full Text] [Related]
9. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297 [TBL] [Abstract][Full Text] [Related]
10. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway. Zhang YP; Liu KL; Yang Z; Lu BS; Qi JC; Han ZW; Yin YW; Zhang M; Chen DM; Wang XW; Li W; Xin H Cell Cycle; 2019 Oct; 18(19):2432-2446. PubMed ID: 31448674 [TBL] [Abstract][Full Text] [Related]
11. NEDD9 crucially regulates TGF-β-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness. Morimoto K; Tanaka T; Nitta Y; Ohnishi K; Kawashima H; Nakatani T Prostate; 2014 Jun; 74(8):901-10. PubMed ID: 24728978 [TBL] [Abstract][Full Text] [Related]
12. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913 [TBL] [Abstract][Full Text] [Related]
13. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787 [TBL] [Abstract][Full Text] [Related]
14. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation. Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612 [TBL] [Abstract][Full Text] [Related]
15. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520 [TBL] [Abstract][Full Text] [Related]
16. Down-regulating ribonuclease inhibitor enhances metastasis of bladder cancer cells through regulating epithelial-mesenchymal transition and ILK signaling pathway. Xiong D; Liou Y; Shu J; Li D; Zhang L; Chen J Exp Mol Pathol; 2014 Jun; 96(3):411-21. PubMed ID: 24768914 [TBL] [Abstract][Full Text] [Related]
17. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. Bhat FA; Sharmila G; Balakrishnan S; Arunkumar R; Elumalai P; Suganya S; Raja Singh P; Srinivasan N; Arunakaran J J Nutr Biochem; 2014 Nov; 25(11):1132-1139. PubMed ID: 25150162 [TBL] [Abstract][Full Text] [Related]
18. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Zhang Z; Liu ZB; Ren WM; Ye XG; Zhang YY Int J Mol Med; 2012 Oct; 30(4):856-62. PubMed ID: 22797360 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of SPINK1-positive prostate cancer. Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222 [TBL] [Abstract][Full Text] [Related]
20. Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Kolijn K; Verhoef EI; van Leenders GJ Oncotarget; 2015 Sep; 6(27):24488-98. PubMed ID: 26041890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]